TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

136 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

123 studies on the map

Autologous Stem Cell Transplant for Crohn's Disease — Icahn School of Medicine at Mount Sinai, New YorkA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamAn Open-label Study of AZD0120 in Adults With Multiple Sclerosis — Research Site, TucsonEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaA Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases — Stanford Neuroscience Health Center, Palo AltoA Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis — Stanford Multiple Sclerosis Center, Palo AltoStudy of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis — GI Alliance, Sun CitySub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceAn Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis — Erick H. Alayo Medical Corporation - Gastro SB Clinic, Chula VistaA Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) — Woodholme Gastroenterology Associates, Glen BurnieA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity — Alabama Neurology Associates, BirminghamAutologous Stem Cell Transplantation for Crohn's Disease — UPMC Prebyterian- Adult Gastroenterology, PittsburghA Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Profound Research, LLC, CarlsbadArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaEffect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques — National Institutes of Health Clinical Center, BethesdaLY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Valleywise Health Medical Center, PhoenixAn Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab — National Institutes of Health Clinical Center, BethesdaStudy of DISC-0974-201 in Participants With IBD and Anemia — One of a Kind Clinical Research Center, LLC, ScottsdaleSelenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies — Northwestern University, ChicagoA Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis — Investigational Site Number: 8400009, EscondidoA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease — Mayo Clinic in Arizona - Scottsdale, ScottsdaleAmitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease — University of Michigan, Ann ArborSolriamfetol for the Treatment of Multiple Sclerosis Fatigue — Johns Hopkins University, BaltimoreTreatment of Moderate to Severe Refractory Crohn's Disease — Mayo Clinic Arizona, ScottsdaleA Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) — Clinnova Research ( Site 1042), AnaheimRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaA Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis — Stanford University Medical Center, StanfordTreatment of Participants With Primary or Secondary Progressive Multiple Sclerosis — University of Kansas Medical Center, Kansas CityTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesTreatment of UC With Novel Therapeutics — Brigham and Women's Hospital, Chestnut HillStudy of Novel Therapeutics for Acute Remedy of Colitis — Brigham and Women's Hospital, Chestnut HillA Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) — Local Institution - 0011, BirminghamTargeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis — Johns Hopkins University, BaltimoreAquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation — University of Michigan, Ann ArborExploring the Utility of [18F]3F4AP for Demyelination Imaging — Yale University PET Center, New HavenEfficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — IMC Gulf Coast Gastroenterology, PC, FairhopeA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — United Medical Doctors, MurrietaCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanHyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis — Byers Hall, San FranciscoA Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease — Investigational Site Number: 8400024, TucsonEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxZinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandGene Editing For Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisA Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis — Arkansas Children's (IP Address), Little RockAllo HSCT for High Risk Hemoglobinopathies — Masonic Cancer Center, MinneapolisMoving Beyond Inflammation as a Therapeutic Target for Crohn's Disease — Cedars-Sinai Medical Center, Beverly HillsA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Gastro Care Institute, LancasterA Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis — Site 024, Canoga ParkA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Gastro Care Institute, LancasterMetformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS) — UBMD Neurolgy, BuffaloR-3750 in Patients With Mild to Moderate Ulcerative Colitis — Amicis Research Center, ValenciaA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamHB-adMSCs for the Treatment of Crohn's Disease — Hope Biosciences Research Foundation, Sugar LandPartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaStudy to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies — Boston Children's Hospital, BostonTargeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin — University of Illinois Chicago, Sickle Cell Center, ChicagoBeta-Hydroxybutyrate Feasibility Treating IBD — University of Texas at Austin, AustinStudy of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis — Xencor Investigative Site, ScottsdaleSickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody — Children's National Hospital, Washington D.C.Obe-cel in Refractory Progressive Forms of Multiple Sclerosis — Stanford University, Redwood CityAssessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy — Sandler Neurosciences Building, Neurological Clinical Research Unit, San FranciscoNasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis — Brigham and Women's Hospital, BostonPatient Preference for Subcutaneous vs. Intravenous Immune Therapy — UPMC Hillman Cancer Center, PittsburghNon-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis — University of Washington, SeattleEfficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis — University of Kansas Medical Center, Kansas CityA Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease — Mirador Therapeutics Selected Site, BirminghamComparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection — University of Kansas Medical Center- Sleep, Health and Wellness Laboratory, Kansas CitySCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamA Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease — Mayo Clinic in Arizona - Scottsdale, ScottsdaleLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: — Mayo Clinic in Arizona - Scottsdale, ScottsdaleA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — AZ Gastro Care, ChandlerA Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis — Profound Research, LLC, CarlsbadA Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years — Boston Clinical Trials Inc - Internal Medicine, BostonStudy of Panobinostat (LBH589) in Patients With Sickle Cell Disease — Augusta University, AugustaA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease — Digestive Health Specialists /ID# 266216, DothanReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenAssessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. — University of Alabama at Birmingham Medical Center, BirminghamA Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis — AZ Gastro Care - Chandler, ChandlerAlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion — New York Medical College, ValhallaLow Dose IL-2 for the Treatment of Crohn's Disease — Boston Children's Hospital, BostonStandardized Microbiota Transplant Therapy in Crohn's Disease — University of Minnesota, MinneapolisIntravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease — Children's National Hospital, Washington D.C.A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis — One of a Kind Clinical Research Center, ScottsdaleA Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. — GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400020, Sun CitySafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — UAMS Medical Center, Little RockSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis — Univ. of California, San Francisco Health Care, OaklandMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoBiomarker-based Trial of NPC-1 for Alzheimer's Pathology — Massachusetts General Hospital, BostonRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraStudy to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis — The University of Texas Health Science Center at Houston, HoustonCentral Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy — National Institutes of Health Clinical Center, BethesdaAlendronate for Osteonecrosis in Adults With Sickle Cell Disease — UC Davis Comprehensive Cancer Center, SacramentoPET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases — Brigham MS Center, 60 Fenwood Road, BostonMyeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease — University of California Los Angeles, Los AngelesTargeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) — National Institutes of Health Clinical Center, BethesdaStudy of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease — University of Illinois at Chicago, ChicagoMolecular Imaging of NET Using [C-11]MRB-PET in MS — Brigham MS Center, 60 Fenwood Road, BostonHaploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease — City of Hope Medical Center, DuarteRelationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET — St. Jude Children's Research Hospital, MemphisMinimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease — Children's National Health System, Washington D.C.T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias — Children's Hospital of Pittsburgh of UPMC, PittsburghTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamPilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy — Connecticut Children's Medical Center, HartfordA Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease — University of Illinois at Chicago College of Medicine, ChicagoTocilizumab for Acute Chest Syndrome — University of Chicago, ChicagoStem Cell Transplantation in Crohn's Disease — Cedars-Sinai Medical Center, Los AngelesEvaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis — The University of Texas Health Science Center at Houston, HoustonInvestigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects — Massachusetts General Hospital, BostonGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesPET Imaging of Vaso-Occlusive Crisis (VOC) in SCD — UPMC, PittsburghThe Use of Butyrate Therapy in Pediatric Ulcerative Colitis — Children's Hospital Los Angeles, Los AngelesMechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype — University of Michigan, Ann ArborCognitive Remediation Intervention to Prepare for Transition of Care — University of Alabama at Birmingham, BirminghamA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenVancomycin Study in Multiple Sclerosis (MS) — Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New YorkCannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain — Mount Sinai Hospital, New YorkPrecise Infliximab Exposure and Pharmacodynamic Control — Children's Hospital of Los Angeles, Los AngelesHome-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) — NYU Langone Health, New YorkDB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease — Direct Biologics Investigational Site, Aurora